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Medulloblastoma is the most frequently occurring childhood malignant brain tumour, 
affecting 1 of 5 children presenting with a brain tumour, between the ages of 0 and 9 years. 
The basic prognostic stratification that relies on clinical and histological findings alone has 
proven unsatisfactory as an outcome predictor. Distinct molecular genetic profiles have been 
described, with four molecular variants of medulloblastoma with specific demographic and 
prognostic features. These are the WNT subgroup, SHH subgroup, Group 3 and Group 4 
tumours.  
The aim of this study was to describe the expression status of β-catenin, and MYCN, using 
IHC and FISH respectively, and to correlate these findings with clinico-pathological and 
demographic characteristics and clinical outcome. 
Materials and Methods 
This study was a nested retrospective analytical study, reviewing 54 cases of childhood 
medulloblastoma diagnosed between 1988 and 2014.  
Results 
Classic histology accounted for 40.7% of cases, LCA 37%, ND 16.7% and 5.6% MBEN). Based 
on B-catenin IHC, the WNT subgroup accounted for 16.7% of cases. This group had no 
mortalities or recurrences. Seven patients showed amplification of MYCN gene. The SHH 
group, defined by ND/MBEN histology and/or MYCN amplification, accounted for 27.7% of 
patients. Non-WNT/non-SHH tumours 30 patients (55.6%) showed a male predilection, and 
accounted for 37.5% recurrences and 50%. mortalities also falling in this group.  
Conclusions 
Nuclear B-catenin identifies WNT tumours. Nodular desmoplastic morphology is useful in 
identifying some, but not all cases of SHH group medulloblastomas. MYCN positive tumours 
also showed classical, and LCA morphology.. Patients of all the beta-catenin positive cases 
were free of recurrence and alive at last follow up. Patients with MYCN amplification and 
non-ND histology (LC/A or classic) had poorer outcomes than patients with ND histology. 
One patient showed both MYCN amplification and nuclear B-catenin translocation, and had 
good clinical outcome. This finding requires validation with other molecular techniques. 
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Brain tumours are the second most common malignancy in children.1,2 Despite 
the importance of brain tumours, there is limited published data examining this 
group of patients, in South Africa and the African continent as a whole. There 
have been extensive and continual advances in paediatric cancer patient care 
over the last two decades; however brain tumour patient outcomes remain 
generally poor compared to outcomes of other childhood malignancies.  
 
Medulloblastoma is the most common childhood malignant brain tumour. The 
prognostic stratification of medulloblastoma patients has been based on 
histological classification, as well as patient demographic and diagnostic findings. 
This basic classification has proved unsatisfactory as an outcome predictor, with 
survivors suffering serious long-term effects, particularly from over-treatment. 
 
Recently, extensive work has been done to evaluate the molecular characteristics 
of medulloblastomas, in a bid to provide insights into the molecular biology of 
this potentially curable disease, and possibly facilitate improved prognostic and 
therapy planning process, and subsequently to facilitate the development of 
novel targeted therapies. These studies have culminated in the description of 
four distinct molecular variants of medulloblastoma, with specific demographic 












1.2 Literature Review 
Medulloblastoma is the most frequently occurring childhood malignant brain 
tumour, affecting one fifth of all children presenting with a brain tumour. 4  It is 
an invasive malignant primitive neuroectodermal tumour of the cerebellum, seen 
most often in children between the ages of 0 and 9 years, but noted to occur at 
any age.5  
 
The current incidence of medulloblastoma is reported as an estimated 0.5 per 
100,000 children below the age of 15.3 Medulloblastomas affect nearly 2 people 
per million per year, affecting children 10 fold more frequently than adults.3 
Medulloblastoma is the second most frequent brain tumor in children following 
Pilocytic astrocytoma, and is the most common malignant brain tumor in 
children, comprising 14.5% of newly diagnosed cases.6  
 
The WHO defines medulloblastoma as a malignant embryonal tumour of the 
cerebellum with preferential manifestation in children, with predominantly 
neural differentiation, and an inherent tendency to metastasize via CSF 
pathways.7 Medulloblastomas most frequently occur in the posterior fossa, in the 
vicinity of the fourth ventricle. 8 
 
The WHO classification recognizes specific histological variants, associated with 
differing outcomes.9 These variants are the classic type of medulloblastoma, 
nodular desmoplastic variant, medulloblastoma with extensive nodularity 
(MBEN), and large cell/anaplastic variant.10  
 
The classic type is characterized by sheets of undifferentiated cells with variable 
neuroblastic differentiation, indicated by the presence of Homer-Wright rosettes 
and palisades.10  
 
The nodular desmoplastic variant, which on histology accounts for between 10% 
and 12% of medulloblastomas, exhibits biphasic architecture of nodules of 
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tumour cells surrounded by prominent amounts of connective tissue. The 
nodules are relatively hypocellular, composed of larger cells characterized by a 
neurocyte-like morphology, in a fine, neuropil-like background. The intervening 
internodular areas are hypercellular, and composed of primitive cells with high 
mitotic activity and proliferative indices. These areas, unlike the nodules, are 
reticulin rich. This variant of medulloblastoma is thought to be slightly more 
favourable prognostically than the classic medulloblastoma.4,10 
 
Medulloblastoma with extensive nodularity (MBEN) differs morphologically 
from the related nodular/desmoplastic variant by showing an expanded lobular 
architecture, characterized by enlarged reticulin free zones that are 
characterized by abundant neuropil-like material.11 
 
The large cell/anaplastic variant of medulloblastoma represents approximately 
4% of these tumours, and are considered to be the most aggressive variant. 12 
They show large, polygonal cells, nuclear pleomorphism and prominent nucleoli. 
Necrosis is a prominent feature.13 
 
Histopathological subtyping has been shown to be a strong prognostic factor in 
certain patients, particularly the desmoplastic and anaplastic subtypes. 14 
However differences in risk stratification and outcomes despite the same 
histologic subtype, particularly for the classical and LC/A variants, have limited 
its value. 15 
 
Since 3 decades ago, medulloblastoma prognostic stratification has been based 
on this histological classification, as well as patient demographic and diagnostic 
findings, that include age at presentation, metastatic status at diagnosis, and 







Based on these features, patients are stratified into two groups: 
 
a) Standard /Low risk: characterized by age of more than 3 years old, non-
metastatic disease, total or near- total resection.17 
 
b) High risk: Leptomeningeal metastases at presentation and / or 
incomplete resection.18 
 
This basic classification has proven unsatisfactory as an outcome predictor, with 
survivors suffering serious long-term effects, particularly from over-treatment.19 
The current treatment modalities include surgical resection, radiotherapy and 
chemotherapy, with a cure rate of about 70%.20 However, there is a continuing 
need to minimize overly aggressive therapy in patients with low-risk disease, to 
limit the occurrence of therapy associated complications such as cognitive 
impairment, stroke, neuropathies, seizures and secondary malignancies.21 
 
Recent extensive study of the molecular characteristics of medulloblastomas 
using cytogenetic and genomic studies have resulted in the definition of distinct 
genetic profiles and pathway signatures that have been correlated with specific 
clinicopathological features.3 These studies have culminated in the description of 
four molecular variants of medulloblastoma, with specific demographic and 
prognostic features. 
 
These variants are the Wingless-Type (WNT) subgroup, Sonic Hedgehog (SHH) 
subgroup, Group 3 and Group 4 tumours.16  
 
Two of these molecular subgroups have lent themselves to extensive study, due 
to the identification of consistent distinct genetic profiles and molecular markers 
that are specific and recurrent, based on their similarities to hereditary 
syndromes with a proclivity for development of medulloblastomas. They are the 
WNT subgroup and the SHH subgroup.3  
The Group 3 and 4 tumour subgroups are less well characterized, with multiple 
but non-recurrent molecular characteristics.  
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The Wingless-type (WNT) Subgroup. 
This is the least common of the medulloblastoma subgroups, occurring in only 
10% of cases.22 It is however the most curable and has the best prognosis of all 
the subtypes, with only rare metastasis to the neuraxis, and with more than 90% 
of patients surviving on current treatment modalities offered.23 These tumours 
show a predominance of classic histology, with low incidences of metastatic 
disease. Rarely, the large cell anaplastic variants are seen.22 Males and females 
are equally affected, and the mean age at diagnosis is 10 years, with an age range 
extending to adulthood. 16 Genomic sequencing studies show that up to 90% of 
these tumours show activating mutations in CTNNB1 (β -catenin, chromosome 
3p21), encoding a pivotal molecule in the canonical WNT signaling pathway. 24,25. 
 
This group is eponymously designated after the predominant expression of 
components of the canonical WNT signaling pathway, a signal transduction 
pathway with a complex network of proteins best known for their roles in 
embryogenesis and cancer.26  The major molecules within the Wnt/APC signal 
transduction pathway are the Adenomatous Polyposis coli (APC) and β-catenin 
proteins. Wnt/Wg genes, which are related to Wingless in Drosophila, encode 
several secreted proteins with key roles in development, cell fate and 
patterning.27 In the absence of Wnt proteins, cells employ active measures to 
maintain low levels of the WNT signaling protein β–catenin.28 At baseline, β -
catenin is phosphorylated at its N-terminus by glycogen synthase kinase- 3β 
(GSK-3β), targeting β-catenin for degradation by the ubiquitin–proteasome 
pathway.29 
 
The aberrant activation of the WNT signaling pathway represents a major 
oncogenic process that is an integral part of the evolution and development of 
many epithelial cancers, including colorectal cancer.30 It has been demonstrated 
that a small percentage of sporadic medulloblastomas, and few inherited forms 
as in Turcot syndrome, are initiated by activating WNT pathway mutations, 
characterized by the stabilization of β-catenin and constitutive transcription by a 
β-catenin/T-cell factor (Tcf)-4 complex.31 Activation of this pathway prevents the 
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cells from either entering G1 arrest or undergoing terminal differentiation, and 
induces resistance to apoptosis. The end result is cellular proliferation.32 
Ellison et al, 23 in a study examining β-catenin status of childhood 
medulloblastomas, indicated that nuclear accumulation of this marker, which is 
in keeping with WNT group of tumours, showed significantly better overall 
survival and event free survival, indicating that it may be a marker of favourable 
outcomes in medulloblastoma patients.  
 
The Sonic Hedgehog (SHH) Subgroup. 
The SHH subgroup shows a bimodal age peak, arising in infants and young 
children on one end of the spectrum and adults on the other.3 There is no sex 
predilection, and metastatic involvement of the neuraxis is an uncommon 
finding.33 The prognosis is favourable for infants and intermediate for other age 
groups.16 
  
In the 1990s, Gorlin syndrome was attributed to inherited mutations of the 
Patched 1 (PTCH1) tumour suppressor gene on chromosome 9q22.32,34 a finding 
that paved the way for studies that demonstrated recurrent somatic mutations of 
PTCH1 in sporadic medulloblastomas.35 The sonic hedgehog (SHH) pathway, a 
developmental signalling axis normally inhibited by PTCH1 protein, is aberrantly 
activated in about 30% of all medulloblastomas.36 Activation of SHH signalling in 
these tumours is as a result of recurrent mutations and/or copy number 
aberrations that target multiple specific levels of the pathway.37 In the absence of 
signal, the transmembrane protein Patched1 (Ptc1) keeps the pathway turned off 
by inhibiting the function of Smoothened (Smo), a second transmembrane 
protein.38 Sonic Hedgehog (Shh) protein, a secreted protein, binds to and 
inactivates Ptch1, allowing activation of Smo. Smo then triggers target gene 
transcription through the Gli family of transcription factors.37 The mechanism by 
which Shh inhibits Ptc1 and Ptc1 inhibits Smo is not understood in mammals.  
 
The common genomic alterations in this subgroup include mutations of PTCH-1 
(chromosome 9q22.3), SMO (7q32.3), or SUFU (chromosome 10q24.32) that 
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disrupt sonic hedgehog signaling, GlI2 amplification (chromosome 2q14), and 
MYCN amplification (chromosome 2p24.3) with MYCN overexpression.3, 8, 39  
 
The predominant histologic variants in this subtype include the 
nodular/desmoplastic type, with a small proportion of the classic and LCA 
types.8 
 
Group 3 tumors, which account for 25% of medulloblastomas, arise in young 
children, and to a lesser extent in infants.3 A male predilection has been 
described. This subtype has the worst prognosis, and finding of metastases to the 
neuraxis is frequent.14 Several chromosomal aberrations have been described, 
including gains on chromosomes 1q, 7, 17q, and 18q, as well as losses on 5q, 8, 
10q, 11p, and 16q. Isochromosome 17q is present.16 MYCC amplification (but not 
MYCN) and marked over expression are common. 3 
Histologically, this group shows LCA and classic morphology.  
 
Group 4 tumours arise most frequently in children, and also show a male 
predilection.3,9 Infants and adults may also be affected. Metastasis to the neuraxis 
is frequent. The prognosis for this group of tumours is considered 
intermediate.16 The described chromosomal aberrations include CDK-6 gene 
amplification, Isochromosome 17q, and involvement of the 
neuronal/glutamatergic pathway.40 There is minimal MYC family expression.3 
The histologic variant seen in group 4 tumours is most commonly the classic 
variant, but LCA histology is also noted.16  
 
Statistical analysis of these 4 subgroups have revealed significant subgroup-
specific clinical features, including patient age at diagnosis, sex, histology, 
metastatic status, and somatic variations, correlated with cytogenetic 
aberrations, providing an improved outcome prediction scheme.27 
 
β-catenin 
Evidence of the involvement of the WNT cell signaling pathway in 
medulloblastoma first came to light from genetic studies of patients with Turcot 
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Syndrome, a syndrome characterized by germ-line mutations in the 
Adenomatous Polyposis Coli (APC) gene, who exhibit a 92-fold risk of developing 
medulloblastoma.  
Sporadic medulloblastoma shows mutations in CTNNB1 (β-catenin), Axin-1, and 
APC, whose phenotypic demonstration can be elucidated by 
immunohistochemical nuclear localization of β-catenin.41 This finding is fairly 
specific for WNT group of medulloblastomas, making this a fairly specific marker 
of this subgroup.3,43 
 
MYCN 
Three MYC proteins have been described in genomic studies of medulloblastoma. 
They are MYC, MYCN and MYCL1.42  These proteins are important because they 
appear to demonstrate different roles in the different medulloblastoma 
subgroups. 43 , 44  The expression and amplification of MYC and MYCN in 
medulloblastoma have been evaluated extensively, as they have previously been 
associated with poor outcomes and highly aggressive tumours.45, 46 
MYCN amplifications are seen to most commonly occur in the SHH subgroup, 
with a few occurring in group 4 tumours, and rarely in group 3.27 Patients with 
MYCN amplification have a substantially worse prognosis than those without 
amplification, a finding that holds true for all patients.47 Bearing in mind the 
fairly specific finding of nodular desmoplastic histology in SHH tumours, the 
finding of these two features is fairly specific for this subgroup, and would allow 
the evaluation of outcomes in this subgroup that are generally regarded as 
having favourable outcomes.3 
 
This study is nested within a larger parent study that aims to collect data on 
childhood brain tumours at Red Cross Children’s Hospital, a regional centre in 








1.3 Study Justification 
The aim of this study was to describe the expression status of β-catenin, and 
MYCN, using immunohistochemistry and fluorescent in –situ hybridization 
(FISH) respectively, and to correlate these findings with the various clinico-
pathological and demographic characteristics of the tumours including patient’s 
age, sex, histopathological subtype and clinical outcome.  
 
This study will set the background for further molecular characterization of 
medulloblastomas into the four molecular subtypes in the larger study that will 
include additional molecular investigations.  
In order to diagnose and classify medulloblastomas into these genetic groups in 
practice, it is necessary to validate the genetic and IHC markers in formalin-fixed 
paraffin-embedded (FFPE) tumour tissue, comparing these findings with 
demographic and survival data in order to verify the usefulness of each marker 
for diagnostic practice. 
 
1.4 Study Objectives 
Main Objective:  
To determine the β–catenin and MYCN expression status of medulloblastoma 
cases diagnosed at Red Cross Children’s Hospital. 
 
Specific Objectives:  
 
1. To collect demographic and outcome data for childhood 
medulloblastomas diagnosed at RCCH. 
2. To determine the β-catenin and MYCN expression status of these tumours 
by immunohistochemistry and fluorescent in situ hybridization (FISH) 
respectively, using standardized techniques. 
 
3. To correlate this demographic data with the patterns of expression of β-
catenin and MYCN. 
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2.0 Study Design and Methodology 
2.1 Study Design 
This study was a nested retrospective analytical study, reviewing cases of 
childhood medulloblastoma diagnosed between 1988 and 2014.  
 
             2.2 Study setting and population 
This study was conducted at the Red Cross Children’s’ Hospital Cape Town, 
Pathology Department. This is a regional referral Centre in the Western Cape, 
South Africa.   
The study was nested within a larger study examining Paediatric Brain tumours 
in South Africa, whose lead principle investigator is Prof. Anthony Figaji 
(Paediatric Neurosurgery). 
This study sought and received ethical approval from the University of Cape 
Town Faculty of Health Sciences Ethics Committee (HREC/REF: 377/2014). 
 
2.3 Sample Size 
The sample size was based on convenience sampling, of cases with diagnostic 
material, clinical information available, and funding limitations. 
 
2.4 Methods 
2.4.1 Inclusion and exclusion criteria 
All cases with histologically confirmed diagnosis of medulloblastoma, that also 
had clinical information available, were included. Any case in which tissue blocks 
and or adequate clinical information were not available, was excluded. 
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2.4.2 Recruitment and Enrollment 
Cases were selected through a consecutive review of neurosurgical, oncology and 
pathology databases at the Red Cross Children’s Hospital.  
All medulloblastoma patients with a histological diagnosis managed at RCCH 
over the stated period, with tissue blocks and clinical information were included. 
Demographic and relevant clinical information of these cases were retrieved 
from patient files and recorded in data sheets. 
 
2.4.3 Research Procedures and Data Collection Methods 
Medulloblastoma patients were identified from neurosurgery and oncology 
databases, and searched for against pathology records. Archived slides and 
Formalin fixed, paraffin-embedded archival tissue blocks from these cases were 
retrieved and reviewed to confirm the diagnosis and histological sub-typing of 
medulloblastoma, according to the 2007 WHO classification for Central Nervous 
System tumours. 
The patients were categorized into specific age groups: Infants (<3 years), 
children (3-10 years and over 10 years), as performed for similar studies27, and 
as described for risk stratification.11 
Immunohistochemistry was conducted using antibodies against β–catenin. 
Fluorescence in situ hybridization was conducted using probes to MYCN. 
 
2.4.4 Laboratory Analysis 
  
Microscopy 
Haematoxylin and Eosin (H&E) stained slides were reviewed to confirm 
medulloblastoma diagnosis and histological sub-type.  
 
Description of these characteristics was based on standard diagnostic protocols.  
 
Data were entered into the data collection sheet (APPENDIX I) 
 




The slide showing the best preserved tumour was identified. From the tissue 
block corresponding to the tumour slide identified, 3 micrometre thin tissue 
sections were cut. The sections were floated in a water bath at 370C, and 
transferred to sialinised glass slides, which were dried in an oven at 60 degrees 
for 6 hours.  
 
Automated immunohistochemical staining for β-catenin was performed. (See 
APPENDIX III)  Heat induced epitope retrieval (HIER) was performed. The cases 
were incubated with the primary antibodies for durations defined by 
optimization done in the laboratory, and following the manufacturers’ 
specifications (Novocastra TM Lyophilized Mouse Monoclonal Antibody Beta-
Catenin, APPENDIX III).  All slides were counterstained with Haematoxylin and 
cover slipped. Positive controls were run in parallel for each antibody. 
 
β-catenin expression was evaluated, and cases segregated based on no or 
membrane staining alone, versus cytoplasmic and nuclear positivity in 10% or 
more of the tumour cells. 
 
Fluorescent in situ Hybridization (FISH) 
(APPENDIX III) 
Formalin-fixed paraffin embedded blocks were analysed for MYCN gene 
amplifications via FISH using specific MYCN probes (Vysis LSI N-MYC 
SpectrumGreen/CEP2 SpectrumOrange probe). 
Slide sections of tumour were treated with denaturing buffer, prewarmed to 
73oC for 30 minutes. The slides were immersed in denaturation buffer at 73oC for 
5 minutes. Slides were placed in 70%, 85% and 100% ethanol respectively at 




- Denatured at 73oC for 5 minutes and placed on ice for 2 minutes 
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- Briefly centrifuged 
- Warmed at 37oC for 16hrs 
- Washed in solution to remove surplus/free probe material 
- 10µl of probe mixture was added to the slide (2µl probe + 8µl buffer) 
- Slides were cover slipped 
- Incubated at 37oC for 16hrs 
- Washed in solution to remove surplus/free probe material 
- 10µl of DAPI (complementary dye) was applied and the slide cover-
slipped. 
 
The slides were then visualized under a fluorescence microscope using 
appropriate filter sets.  Under a Zeiss fluorescence microscope (Zeiss, Germany), 
the signals of the 2 probes in only intact nuclei were visualized through a triple 
bandpass filter (Vysis). Counting of hybridization signals was performed by 
examining a minimum of 50 distinct, non-overlapping nuclei were assessed per 
case. 
2.4.5 Quality Assurance 
 
1. Standard operating procedures were observed for routinely used stains 
2. Suitable positive controls as defined by the manufacturer, were included 
for each slide for immunohistochemistry. 
 
The slides were then visualized under a fluorescent microscope using 
appropriate filter sets. A minimum of 50 distinct, non-overlapping nuclei were 
assessed per case.  
 
The findings of both FISH and immunohistochemistry were collated and 
statistical analysis was undertaken, along with patient demographic and 
outcome data. Slides were digitally photographed using the Olympus digital 






Privacy and Confidentiality 
Patient anonymity was preserved throughout the study process. Records were 




Ethical approval was sought from the Human Ethics Board of the University of 
Cape Town before commencement of the study. The study does not impact on 
current patient care. All patient records were de-identified to maintain patient 
anonymity when analyzing the samples.  
The parent study has received ethical approval. Funding was sourced from the 
parent study. 
 
2.4.6 Data Management and analysis:  
Data were recorded using a data sheet and then entered into an MS Excel 
spreadsheet (APPENDIX I). Statistical analysis was done using SPSS version 20.0 
(SPSS Inc., Chicago). Values were represented as means and percentages. Chi 
square test (or Fisher’s exact test when number was <5) was performed to 





54 cases met the inclusion criteria and were included in the study.  51.9% (n=28) 
of the patients were female and 48.1% were male. The mean age of the patients 
was 65.48 months (5years, 5 Months). 
 
Based on age categories, 24,1% of patients were below the age of 3 years (See 
Table 1 below). 
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The tumours were predominantly midline (79.6%; n=43), with only 5.7% (2 
right and one left) located laterally. There were 8 cases for which tumour 
location was unknown. 
 
22.2% of the tumours were less than 4.1cms. 57.4% of tumours were greater 
than 4.1cms. Size was not known for 11 cases (20.4%). 
 
A summary of the findings is represented in Table 1. 
 
Number 
(n=54)              % 
Sex Male 26 48.1% 
 Female 28 51.9% 
Age < 3 years 13 24.1% 
 3-10 years 37 68.5% 
 > 10 years 4 7.4% 
Site of Tumour Midline 43 79.6% 
 Right 2 3.7% 
 Left 1 1.9% 
 Unknown 8 14.8% 
Tumour size <4.0cm 12 22.2% 
 >4.0cm 31 57.4% 
 Unknown 11 20.4% 
Risk stratification Low risk 19 35.2% 
 High risk 34 63.0% 
  Unknown 1 1.9% 
Extent of Resection Biopsy 3 5.6% 
 Subtotal 4 7.4% 
 Near-total 22 40.7% 
 Total 25 46.3% 
Radiotherapy Yes 44 81.5% 
 No 10 18.5% 
Chemotherapy Yes 40 74.1% 
 No 14 25.9% 
Tumour Recurrence None 46 85.2% 
 Recurrence 8 14.8% 
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Mortality Status Alive 41 75.9% 
 Deceased/palliation 12 22.2% 
β -catenin status Membrane only 45 83.3% 
 Nuclear/cytoplasmic 9 16.7% 
MYCN Status (N=30) Negative 23 76.7% 
 Amplified 7 23.3% 
Table 1: Data Summary (N=54; MYCN N=30) 
 
 
 Histological subtypes. 
Classic histology accounted for 40.7% (n=22) of cases, being the most frequent 
histological subtype. Large cell / Anaplastic subtype was the second most 
common, accounting for 37% (n=20) of cases of medulloblastoma (See Figure 
1)). Only 3 cases (5.6%) of medulloblastoma with extensive nodularity (MBEN) 
























Figure 3: Large cell / anaplastic subtype of medulloblastoma with large atypical 
mitotic figure (H&E, x40 magnification) 
 
 
Figure 4: Large cell / anaplastic subtype of medulloblastoma with cell wrapping 









Figure 6: Nodular desmoplastic subtype of medulloblastoma (H&E, x4 magnification) 
 
 
Figure 7: Reticulin stain showing no reticulin fibres within the nodules of the 
desmoplastic subtype of medulloblastoma (Reticulin stain, x10 magnification) 
 
Based on clinical criteria described, 63% (n=34) of cases were classified as high 




 12 cases showed mixed histology, with 7 cases of the classic or large cell 
anaplastic tumours showing nodular desmoplastic areas, and 4 cases with focal 
anaplasia (figure 8). 
 
 
Figure 8: Biphasic tumour pattern showing large cell /Anaplastic and classic patterns 
(H&E, x10 magnification) 
 
 
Histological Subtype and outcome. 
Classic histological subtype accounted for the largest percentage of mortality 
/palliation outcomes (41.7%; n=5), followed by large cell/anaplastic (33.3%). 
Neither Nodular Desmoplastic nor MBEN had any mortality outcomes (Table 2). 
 
 Mortality Status 
Histological subtype Alive (n=41) Deceased/palliat
ion (n=12) 
Unknown (n=1) 
Classic 16 (39.0%) 5 (41.7%) 1 (%) 
ND 6 (14.6%) 3 (25.0%) 0 (0%) 
MBEN 3 (7.3%) 0 (0.0%) 0(0%) 
LC/A 16 (39.0%) 4 (33.3%) 0(0%) 
Table 2: Histological Subtypes and Mortality status Cross tabulation  
 




β-catenin staining (WNT Group) 
With regards to β-catenin status, 16.7% (n=9) showed nuclear-cytoplasmic 
staining. 26% (5/19) of these patients were in the low risk group, and 11% 
(4/34) were in the high-risk group. (Figure 9 to 12). 
 










Figure 11: Variable β-catenin nuclear staining (x 40 magnification) 
 
Figure 12: Moderate cytoplasmic and nuclear β-catenin staining (x 40 magnification) 
 
 
β-catenin and histological subtypes. 
Of the cases that showed aberrant nuclear-cytoplasmic β-catenin staining, 4 
showed classic histology, and 4 LC/A, with one showing ND morphology.  Two of 
the LCA cases and one classic case showed >50% staining. The others showed 




β-catenin and outcome. 
 




 Mortality Status 
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β-catenin status Alive (n=41) Deceased (n=12) 
Membrane only 32 (78.0%) 12 (100.0%) 
Nuclear/cytoplasmic 
(‘positive’) 
9 (22.0%) 0 (0.0%) 
Table 3: β -catenin - Mortality status Cross-tabulation 
 
This finding approached, but did not however attain statistical significance 
(p=0.066, Fisher’s exact test, one sided). 
 
β-catenin status had a trend towards association with tumour recurrence 
(p=0.065, Fisher’s exact test, one sided), in that none of the tumours with 
aberrant β-catenin staining recurred, but this did not reach statistical 
significance. A cross tabulation of recurrence and β-catenin status is represented 
in Table 4.  
 
There was no evidence of an association between β -catenin status and clinical 
risk status (p=0.357). 
 
 
 Tumour Recurrence Total 
No recurrence Recurrence 
β-catenin 
membrane 
No. 37 8 45 
% with Tumour Recurrence 80.4% 100.0% 83.3% 
Nuclear-
cytoplasmic 
No. 9 0 9 
% with Tumour Recurrence 19.6% 0.0% 16.7% 
                          Total 46 8 54 
Table 4: β -catenin- Tumour Recurrence Cross tabulation. 
 
 
MYCN and outcome  
Thirty cases were stained for MYCN using FISH probes (Figures 13 and 14 




Figure 13: MYCN FISH not amplified showing two green and red signals within each 















Figure 14: MYCN FISH amplification (Cases 1,2- triple filter; Cases 3, 4-green filter) 




The histological subtypes of these cases were 2 classic, 3 nodular/desmoplastic 






Comparison with tumour recurrence and mortality/palliation are tabulated in 





Tumour Recurrence Total 





















Table 5: MYCN Status – Tumour Recurrence Cross tabulation 
 
 

















Total 14 6 30 
Table 6: MYCN status - Mortality status Cross tabulation 
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These findings however, did not achieve statistical significance (p=0.225 and 




15 cases were classified as belonging to the SHH group, classified based on 
Nodular desmoplastic/MBEN morphology, and/or MYCN over-expression. 
Nine of these patients were below the age of 3 years, with 18 aged 3 to 10 and 3 
over the age of 10. Seven patients were male (46.7%). Seven cases each were 
classified as high or low risk respectively, with risk status unavailable for one.  
This group accounted for 27.7% of patients. 
 
Nine patients in this group were alive at last follow-up. These cases showed 
MBEN histology (3 cases), Nodular desmoplastic histology (5 cases) and classic 
histology (1 case). Three patients showed MYCN amplification (2 ND, 1 Classic). 
MYCN status was unknown for 6 of these patients. 
 
Six of the patients were deceased or on palliation (40%), with 3 showing ND 
histology, two LC/A and one classic. Of these, 5 had recurrences. One was not 
operated on due to the size of the tumour, and its increased growth despite 
chemotherapy. For 3 of these patients, MYCN status was unknown. 
 
 
 Frequency (n=15) Percent 
No recurrence 10/15 66.7% 
Recurrence 5/15 33.3% 
 
Alive 9 60% 
Deceased/palliation 6 40% 
Table 7: SHH group and recurrence/outcome cross tabulation. 
 
 
 Non Wnt/Non SHH” group 
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This group was composed of cases that did not fit the above descriptive criteria, 
which is no nuclear β -catenin, non-ND or MBEN histology and no MYCN 
amplification. 
 








 Number (n=30)              % 
Sex Male 17 56.7% 
 Female 13 43.3% 
Age < 3 years 9 30.0% 
 3-10 years 18 60.0% 
 > 10 years 3 10.0% 
Risk stratification Low risk 7 23.3% 
 High risk 23 76.7% 
Tumour Recurrence None 27 90.0% 
 Recurrence 3 10.0% 
Mortality Status Alive 23 76.0% 
 Deceased 6 20.0% 
 Unknown 1 4.0% 
 















Table 9 summarizes the tumour size, therapy and outcomes of the MYCN and 





Resection RXT CXT Recurrence Deceased/palliation 
Bigger 4 Y Y No No 
Bigger 4 No Y Yes Yes 
Unknown 3 Y Y No No 
Bigger 4 Y Y No No 
Bigger 3 Y Y Yes Yes 
Bigger 4 Y Y No No 
Bigger 1 No Y No Yes 
Aberrant β-catenin 
Smaller 3 Y Y No No 
Bigger 2 Y No No No 
Under 3 (10%) 
3 to 10 (60%) 
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Unknown 3 Y Y No No 
Unknown 3 Y Y No No 
Bigger 4 Y Y No No 
Bigger 4 Y Y No No 
Smaller 4 Y Y No No 
Smaller 4 Y Y No No 
Bigger 4 Y Y No No 





Medulloblastoma is a complex disease, characterized by described genetic 
changes that have facilitated a molecular classification of these tumours.  The 
molecular classification of medulloblastomas is aimed at enabling the prediction 
of the pathogenesis and biological behavior.  
 
Historically, tumour classification has been based on histological classification 
alone, and management based on clinical characteristics that stratify patients 
into low or standard risk groups. However, studies have shown varied responses 
to treatment, and varied outcomes have been described for the same histologic 
subtype, with patients who are potentially curable with less aggressive 
management strategies suffering significant treatment related morbidity, thus 
highlighting the need a molecular classification.  Patient management thus far 
has been based on standard therapy protocols (APPENDIX IV) 
There is evidence of unique molecular pathogenetic pathways for 
medulloblastoma. However, there is a need for accessible techniques that can 
identify surrogate markers for these molecular pathways that are potentially 
usable in routine diagnostic pathology, specifically immunohistochemistry and 
FISH. 
 
The aim of this study was to determine the expression status of β-catenin by 
immunohistochemistry and MYCN over-expression by FISH, and to correlate 




Our patient ages ranged from 3 months to 13 years, with a mean age of 5 years 
and 5 months. There was a slight female predominance (51.9% versus 48.1%), 
compared to other demographics that indicate a male preponderance.5 
 
Overall, post-treatment outcomes were comparable to the findings of Gajjar et 
al,20 at 76%, to their recorded 70%. 
 
Using the molecular groups that have been defined for medulloblastoma, and 
using described immunohistochemical, FISH and morphological features as 
surrogate markers, the cases can be divided into the following groups: 
 





SHH group (ND/MBEN 
and MYCN over-
expression) 




9 15 30 
Percentages 16.7% 27.7% 55.6% 
 
β-catenin is a specific marker for the WNT pathway, which has been shown to be 
a category with a more favourable outcome than any of the other groups.23 In a 
study by Fattet et al,48 who looked at the correlation between 
immunohistochemistry findings for nuclear β-catenin staining and compared this 
to genetic mutational status, found that presence of more than 5% nuclear 
staining correlated with CTNNB1 mutational status. 
 
In this study, the WNT subgroup accounted for 16.7% of cases, compared to the 
10% described by Northcott et al.16 Other independent studies have reported 
rates of 12.5%,48 16%,49 and 25%.23 
 
 This group had 2 males and 7 females. The sex ratio for WNT tumour subgroup 
has been reported as 1:1,16 with better outcomes reported in females overall due 
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to their more common representation in the WNT group, as was the case in our 
study population, compared to the nearly 1:1 ratio overall.  
 
Another noted distinction is the incidence of Large cell / Anaplastic morphology, 
which accounted for 33% (n=3) of cases in this group. Generally, this histological 
subtype is considered only a rare occurrence in the WNT group.3 da Silva et 
al41reported an incidence of 18% in their analysis of medulloblastoma. One case 
showed nodular desmoplastic histology and will be discussed in greater detail.  
 
All patients found to have aberrant β -catenin staining were over the age of 3 
years, in keeping with reports of this tumour expression occurring in older 
children.3,16 
 
Clinical risk stratification has all along been a major factor in determination of 
patient management strategies.  
 
Of patients with nuclear/cytoplasmic β-catenin staining (WNT), 5 were classified 
as low risk by clinical criteria, and 4 were classified as high risk. Clinical risk 
status did not show a statistically significant association with either β -catenin or 
MYCN. 
 
All recurrences in our patient population showed nuclear negativity for β-
catenin. Although the p-value for the association between β-catenin expression 
and recurrence and mortality outcome tended toward but did not achieve 
statistical significance, it is of note that all the patients with nuclear β-catenin 
positive tumours are alive at last follow-up (Tables 3 and 4). 
 
Seven patients showed amplification of MYCN gene. The histological subtypes of 
these cases were 2 classic, 3 nodular/desmoplastic and 2 Large cell /anaplastic.  
Two (28.3%) of these patients had tumour recurrence, and 3 (42.9%) are 
deceased. Of the two who had recurrences, their tumours were LCA, both at 
initial diagnosis and recurrence. The third patient had classic histology but 
tumour resection was not possible, and the patient was referred for palliation. 
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Because FISH for MYCN was performed on only 30 of the 54 cases, it may be an 
under-estimation of the occurrence of this genetic amplification.  
 
Of the 7 cases that showed MYCN amplification, they showed Nodular 
desmoplastic, Large cell /Anaplastic and Classical histology, consistent with the 
heterogeneity described for this group of tumours.  
 
Three of the MYCN amplified patients are deceased or on palliation (2 deceased, 
one on palliation, with four months follow-up). The two deceased patients had 
LC/A histology and recurrence of tumour; the other had classic histology, and 
tumour was noted to have increased in size despite chemotherapy. Three of the 4 
living patients showed ND histology and the last was classic. 
 
 
Of cases in the SHH group, classified based on Nodular desmoplastic/MBEN 
morphology, and/or MYCN over-expression,3 this group accounted for 27.7% of 
our patients, a figure in keeping with the 30% described by Northcott et al.16 This 
group has an intermediate prognosis, and can be represented by any of the 
histologic subtypes. 
 
The 15 patients in this group had varied outcomes. Nine were alive at last follow-
up, and these cases showed MBEN histology (3 cases), Nodular desmoplastic 
histology (5 cases) and classic histology (1 case). Three patients showed MYCN 
amplification (2 ND, 1 Classic). MYCN status was unknown for 6 of these patients. 
 
Six of the patients were deceased or on palliation, with 3 showing ND histology, 
two LC/A and one classic. Of these, 5 had recurrences. One was not operated on 
due to the size of the tumour, and its increased growth despite chemotherapy. 
For 3 of these patients, MYCN status was unknown. 
 
Korshunov et al,47 in a study examining MYCN-MB histology in 67 tumours, 
demonstrated heterogeneity of outcomes, clinical biology and tumour genetics. 
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All other tumours that did not fit into the two described groups were together 
considered to be part of the Group 3 and Group 4 tumours (Non-WNT/Non-
SHH). This group consisted of 30 patients (55.6%).  Ellison et al38 described this 
group as representing 55% of their study population. This group represents the 
assumed group 3 and 4 tumours, which account for 25% and 35% of 
medulloblastomas respectively (aggregate of 60%).16 
 
These tumours have a male predilection, and can occur from infancy to 
adulthood.3  Nine of these patients were below the age of 3 years, with 18 aged 3 
to 10 and 3 over the age of 10.  
 
Of the 8 recurrences overall, 3 (37.5%) are in this group, with half of the 12 
mortalities also falling in this group. Group 3 tumours have the worst prognosis, 
with Group 4 tumours showing intermediate prognosis.16 
 
This is however an unsatisfactory categorization, as Group 3 tumours have by far 
the worst prognosis, and should be considered independently. 
 
 
The patient with nodular desmoplastic histology within the WNT group also 
showed MYCN amplification. Based on the B-catenin amplification, it was 
classified in the WNT group. This patient is alive post-treatment. 
MYCN moderate overall expression has been described in WNT tumours,44 but 
is an high expression is an unusual finding. Further molecular studies would be 
needed to further characterise this case.  
 
An observation of note is the finding of mixed subtypes in 12 of our cases.  The 
most common finding was of a nodular /desmoplastic component within a 
predominantly classic or large cell anaplastic tumour (7 cases), followed by focal 
anaplasia, not fulfilling criteria for LC/A, seen in other subtypes (4 cases). 
Classification was based on the predominant component. 
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5.0 Study Limitations 
 
The major limitation to this study is the limited funding that did not allow MYCN 
characterization of all the tumours.  
 
Another limitation is the absence of markers for group 3 and group 4 tumours.  
The parent study aims to address this issue by exploring four antibodies that 
have been described for each sub-type, along with other molecular studies, and 
this data will be collated along with their findings. 
 
The short duration of follow-up for some of the patients included also limits the 
prognostic value gleaned from the findings.  
 
The retrospective nature of the study limited some aspects of clinical 
information, particularly data on radiological staging. Some of the clinical folders 
could not be retrieved. 
 
Finally, for patients who are alive post therapy, the data does not reflect the 
functional outcomes post therapy, an important factor that has informed the 
search for molecular characterization of these tumours.  
 
6.0 CONCLUSIONS 
As described by other authors, β-catenin nuclear translocation serves as a robust 
marker for the WNT group of tumours, which can present with varied histology, 
and generally have good clinical outcome. 
 
Nodular desmoplastic morphology is useful in identifying some, but not all cases 
of SHH group medulloblastomas. MYCN positive tumours also showed classical, 
and LCA morphology. Although for the purposes of this study, cases showing 
MYCN amplification were considered to belong to SHH group, one case also 
showed aberrant nuclear β-catenin staining. This finding requires validation 
with other molecular techniques.  
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Patients of all the aberrant β-catenin cases were free of recurrence and alive at 
last follow up and this finding approached statistical significance compared to a 
42.9% mortality in the MYCN positive group and 40 % mortality in the SHH 
group as a whole. Patients with MYCN amplification and non-ND histology (LC/A 
or classic) had poorer outcomes than patients with ND histology. One patient 
showed both MYCN amplification and nuclear β-catenin translocation, and had 

























Risk Extent of 
resection 
Radiotherapy Chemotherapy Recurrence Outcome 
1 32 1 1 1 N/A 1 1 2 2 2 1 1 1 1 
2 37 2 2 2 N/A 1 1 1 1 4 1 2 1 1 
3 29 1 2 2 2 1 1 2 2 4 1 1 1 1 
4 88 2 2 4 N/A 1 1 ? 2 2 1 1 1 1 
5 122 3 1 4 N/A 2 1 1 2 3 1 1 1 1 
6 62 2 2 2 N/A 1 ? ? 1 4 1 2 1 1 
7 16 1 2 4 N/A 1 1 2 2 3 2 2 1 1 
8 155 3 1 1 N/A 1 1 1 2 3 1 1 1 1 
9 39 2 2 4 N/A 2 1 2 2 2 1 1 1 1 
10 118 2 2 4 N/A 1 1 ? 1 4 1 2 1 1 
11 27 1 1 2 N/A 1 1 2 2 4 1 1 2 2 
12 113 2 1 1 N/A 1 1 1 1 4 1 2 1 1 
13 88 2 2 4 N/A 1 1 2 1 4 2 2 1 1 
14 41 2 1 2 N/A 1 1 1 1 4 2 2 2 2 
15 136 3 1 1 N/A 1 1 1 2 3 1 1 1 1 
16 45 2 2 2 N/A 1 1 2 2 3 1 1 2 2 
17 12 1 1 4 N/A 1 1 2 2 3 2 1 1 2 
18 39 2 1 4 N/A 2 1 ? 2 3 1 2 1 1 
19 108 2 2 4 N/A 1 1 2 2 3 1 1 1 1 
20 156 3 2 4 N/A 1 1 ? 2 3 1 1 1 1 
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21 72 2 2 4 1 1 1 2 2 3 1 1 1 1 
22 72 2 1 4 2 1 1 2 1 4 2 1 2 2 
23 64 2 1 1 1 1 1 2 2 3 1 1 1 1 
24 88 2 1 1 1 1 1 1 2 3 1 1 1 1 
25 12 1 2 1 1 1 1 2 2 1 2 2 1 1 
26 13 1 1 3 1 1 1 2 2 4 2 1 1 1 
27 108 2 1 1 N/A 2 ? ? 2 3 1 1 1 1 
28 64 2 2 1 1 1 2 2 2 3 1 1 1 1 
29 51 2 1 1 2 1 ? ? 0 3 1 1 1 1 
30 44 2 1 1 N/A 1 ? ? 2 3 1 1 2 2 
31 96 2 2 2 2 1 1 2 1 4 1 1 1 1 
32 84 2 2 1 N/A 1 ? ? 1 4 1 1 1 3 
33 67 2 1 4 N/A 1 1 2 2 3 1 ? 1 1 
34 35 1 1 4 1 1 1 2 1 4 1 2 1 1 
35 72 2 1 4 N/A 1 ? ? 1 4 1 1 1 1 
36 72 2 1 3 1 1 1 1 2 4 1 1 1 1 
37 66 2 2 4 2 1 1 2 2 3 1 1 2 2 
38 69 2 1 1 1 1 1 2 1 4 1 1 1 1 
38 3 1 2 1 1 1 ? ? 2 1 2 2 1 2 
40 96 2 1 4 1 2 1 2 1 4 1 1 1 1 
41 72 2 2 4 1 1 1 2 2 3 1 2 1 1 
42 72 2 2 1 1 2 3 2 1 4 1 1 1 1 
43 108 2 1 2 2 2 2 1 1 4 1 1 1 1 
44 96 2 1 1 1 2 1 1 1 4 1 1 1 1 
45 30 1 2 1 1 1 1 1 2 3 1 1 2 2 
46 95 2 2 4 1 1 1 2 2 3 1 1 2 2 
47 48 2 1 2 1 1 1 2 1 4 1 1 1 1 
48 59 2 1 1 1 2 1 1 1 4 1 1 1 1 
46 96 2 1 3 1 1 1 2 1 4 1 1 1 1 
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50 18 1 1 1 1 1 1 2 2 2 2 2 1 2 
51 72 2 2 1 1 1 1 2 2 4 1 1 1 1 
52 11 1 2 1 2 1 1 2 2 1 2 1 1 2 
53 10 1 2 1 1 1 ? 2 2 4 1 1 1 1 
54 38 2 2 4 1 1 1 2 2 3 1 1 1 1 
Codes provided below. 
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DATA SHEET CODING. 
 
1. Data   number: _______________     
 
2. Age(yrs and months):____________ 
 
3. Age ranges   <3   1 
 3-10   2 
   >10   3 
 
4. Sex:       Female-                            1 
                     Male-                             2 
 
5. Histological Subtype 
Classic          1 
Nodular/Desmoplastic        2 
Medulloblastoma with extensive nodularity      3 
Large cell/Anaplastic        4 
 
6. MYCN Status 
Negative    1 
Positive (amplified)   2 
Not done     - 
 
7. Beta catenin staining 
Membrane     1   (Membrane staining only, or  
nuclear <10%) 
nuclear-cytoplasmic   2   (Cytoplasmic and / nuclear  
staining; >10%; 10-
50%; >50%) 
8. Tumour location  
Midline  1 
Right   2 
Left    3 
Unknown  - 
 
 
9. Tumour size 
Smaller (<4.1cm)  1 
Bigger   (>4.1cms)  2 
Unknown   - 
 
10. Risk 
  Low risk  1 
  High risk  2 
 
11. Extent of Resection 
Biopsy   1 
Subtotal resection  2 
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Near total resection  3 










Yes  1 
No  2 
  




Alive    1 



































High temperature Antigen Unmasking  
Technique for Immunohistochemical  
Demonstration on Paraffin Sections. 
 
Leica Biosystems Newcastle Ltd. 95 8147 Rev A 
  
1. Cut and mount section on slides coated with suitable tissue adhesive. 
2. Deparaffinize sections and rehydrate to distilled water. 
3. Place sections in 0.5% hydrogen peroxide/methanol for 10 minutes (or 
use other appropriate endogenous peroxidase blocking procedure). Wash 
sections in tap water . 
4. Heat 1500mls of the recommended unmasking solution (0.01M buffer, pH 
6.0 (or Epitope retrieval solution, RE 7113)unless otherwise indicated 
overleaf. Until boiling in a stainless steel pressure cooker. Cover but do 
not lock the lid. 
5. Position slides into metal staining racks (do not place slides close together 
as uneven may occur)and lower into pressure cooker ensuring slides are 
completely immersed in unmasking solution. Lock lid. 
6. When the pressure cooker reaches operating temperature and pressure, 
(after about 5 minutes) start a timer for 1 minute (unless otherwise 
indicated on the data sheet). 
7. When the timer rings, remove pressure cooker from heat and run under 
cold water with lid on. DO NOT OPEN LID UNTIL THE INDICATORS SHOW 
THAT PRESSURE HAS BEEN RELEASED> Open lid, remove slides, and 
place immediately in a bath of tap water . 
8. Wash sections in TBS buffer (pH 7.6) for 1x5 minutes 
9. Place sections in diluted normal serum (or RTU Normal Horse Serum) for 
10 minutes. 
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10. Incubate sections with primary antibody. Use antibody diluent RE7133 
(where available). 
11. Wash in TBS buffer for 2x5 minutes.  
12. Incubate sections in an appropriate biotinylated secondary antibody. 
13. Wash in TBS buffer for 2x5 minutes.  
14. Incubate slides in ABC reagent (or RTU streptavidin/peroxidase 
complex). 
15. Wash in TBS buffer for 2x5 minutes.  
16. Incubate slide in DAB or other suitable peroxidase substrate 
17. Wash thoroughly in running tap water. 
18. Counterstain with Haematoxylin, dehydrate and mount. 
 
SOLUTIONS 
0.01M CITRATE BUFFER (PH6.0) OR RE7133 (where available). 
Add 3.8 g of citric acid (anhydrous) to 1.8L of distilled water. Adjust to pH 6.0 
using concentrated NaOH. Make up to 2L with distilled water. 
1mM EDTA 9pH 8.0) or RE 7116 
Add 0.37g of EDTA (SIGMA product coded E-5134) to 1L of distilled water.  
Adjust pH to 8.0 using 1.0M NaOH. 
20mM TRIS/0.65mM EDTA/ 0.65% TWEEN (pH 9.0) or RE 7119 (where 
available) 
Dissolve 14.4g of Tris (BDH product code 271197K) and 1.44g EDTA (SIGMA 
product code E-5134) to 0.55L of distilled water. Adjust pH to 0.9 with 1 M  HCL 
and add 0.3ml Tween 20 (SIGMA product code P-1379) Make up to 0.6L with 
distilled water. This is a 10x concentrate which should be diluted with distilled 
wateras required (eg 15ml diluted with 1350mL of distilled water). 
*in most applications, 10mM phosphate, 0.15M NaCl, pH 7.6 (PBS) can be used 








Lyophilized  Mouse Monoclonal Antibody 
Beta-Catenin 
Product Code:  NCL-B-CAT 
Intended Use  FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC  
PROCEDURES. 
Specificity  Human beta-catenin 
Clone   17C2 
Ig Class  IgG2a 
Antigen Used for  
Immunizations Prokaryotic recombinant protein corresponding to a 160  
amino acid region of the C-terminus of the beta-catenin 
molecule. 
Hybridoma Partner  Mouse myeloma (p3-NS1-Ag4-1). 
Preparation Lyophilized tissue culture supernatant containing 
sodium azide. 
Reconstitute with the volume of sterile distilled water  
indicated on the vial label. 
Effective on Frozen   
Tissue   Yes 
Effective on Paraffin  
Wax Embedded  
Tissue   Yes. 
Recommendations on 
Use Immunohistochemistry: typical working  
dilution 1:100-200.  
High temperature antigen unmasking technique. 60 min  
primary antibody incubation  at 25OC. Standard ABC 
technique on paraffin sections. 
Positive controls IHC: Tonsil, squamous epithelium 
Staining pattern Membrane 
 




Fluorescent in situ Hybridization (FISH) Protocol 
The procedure will take place as follows: 
Formalin-fixed paraffin embedded blocks will be analysed for MYCN gene 
amplifications via FISH using specific MYCN probes. 
Sections of paraffin embedded blocks: 
- Denaturing buffer will be pre-warmed to 73oC for 30 mins. 
- Slides immersed in denaturation buffer at 73oC for 5 mins. 
- Slides placed in 70%, 85% and 100% ethanol respectively at room 
temperature for 1 min each. 
- Slides warmed at 45 oC until ethanol evaporates 
Probes: 
- Denatured at 73oC for 5 mins and placed on ice for 2 mins 
- Briefly centrifuged 
- Warmed at 37oC for 16hrs 
- Washed in solution to remove surplus/free probe material 
- 10µl of probe mixture will be added to the slide (2µl probe + 8µl buffer) 
- Slides will be cover slipped 
- Incubated at 37oC for 16hrs 
- Washed in solution to remove surplus/free probe material 
- 10µl of DAPI (complementary dye) will be applied and the slide cover-
slipped. 
The slide will then be visualized under a fluorescent microscope using 
appropriate filter sets. A minimum of 50 distinct, non-overlapping nuclei will be 
assessed per case.  
The fluorescence in situ hybridization (FISH) technique was performed on tissue 
slides. The Vysis LSI N-MYC SpectrumGreen/CEP2 SpectrumOrange probe, 
designed specifically to detect amplification of the MYCN gene on chromosome 
2p24 using CEP2 as an internal control, was used.  
Interpretation: 
A normal nucleus will show two green signals (MYCN) and two orange signals 
(CEP2) while an abnormal case, positive for amplification of MYCN, will have 6 or 
more green signals. 
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APPENDIX IV 
CHEMOTHERAPY OF BRAIN TUMOURS RX 9941 
 
Commences after the postoperative CT or MR scan and myelogram and within 4 
weeks after surgery. 
 
Week 0: Day 1: Carboplatinum 500mg/m2 IV 
                          Vincristine 1.5mg/m2 
                          Etoposide 100mg/m2 IV 
Day 2-5   Etoposide 200mg/m2 po daily 
 
Week 1-6         Vincristine 1.5mg/m2  IV Weekly 
 
(Dosage for infants: Carboplatinum 16.5mg/kg, Etoposide 3.3mg/kg, Vincristine 
1.5mg/kg 
 
a) Patients under 3 years of age: repeat Carboplatinum + Etoposide (with 
dosage modification) every 3 weeks unless delayed by cytopenia) for a 
total of 8 courses. 
b) Patients over 3 years of age: repeat above (with appropriate dose 
modification) at week 3, unless delayed by cytopenia. 
 
Radiotherapy is given after course 2 of chemotherapy. On completion, 
chemotherapy is recommenced immediately (if blood counts permits) to a 
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